pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
KRAS · news · pharmadog
← back to KRAS
News · KRAS
170
stories
May 6, 26
Clinical Scenario Presentation and Treatment Approach for Progressive Disease
onclive
May 6, 26
Dr Pant on the Mechanism of Action of Daraxonrasib in PDAC
onclive
May 5, 26
Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic Cancer
onclive
May 5, 26
Dr Pant on Managing Toxicities With Daraxonrasib in PDAC
onclive
May 5, 26
Breast Cancer Experts Preview Abstracts to Watch at the 2026 ESMO Breast Cancer Congress
onclive
May 5, 26
The Type of Fat—Not the Amount—Fuels Pancreatic Cancer
onclive
May 5, 26
Dr McGregor on Key End Points of the STRIKE Trial of Tivozanib Plus Pembrolizumab in RCC
onclive
May 5, 26
Dr Kuykendall on the Evolving JAK Inhibitor and Transplant Considerations in Myelofibrosis
onclive
May 5, 26
Coordinating Care in Multiple Myeloma Across Practice Settings
onclive
Apr 30, 26
Securing NIH awards is getting more competitive — and confusing
stat
Apr 29, 26
FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech
biopharma dive
Apr 28, 26
FDA claims Amgen drug data were ‘manipulated’; Erasca slides despite ‘home run’ results
biopharma dive
Apr 28, 26
STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data needed
stat
Apr 28, 26
Updated: AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire Kestrel
endpoints
Apr 27, 26
STAT+: Erasca touts strong, though preliminary, results in trial of pancreatic and lung cancer therapy
stat
Apr 27, 26
Erasca reports RAS cancer drug data after legal threat from Revolution
endpoints
Apr 27, 26
Revolution Medicines threatens to sue Erasca over patent, efficacy claims
endpoints
Apr 24, 26
Lilly tumbles on Foundayo’s shaky week; FDA to issue vouchers for psychedelics
biopharma dive
Apr 22, 26
BridgeBio’s oncology spinoff swaps out CEOs as it seeks to accelerate KRAS work
endpoints
Apr 22, 26
Revolution drug shows promise in early pancreatic cancer
biopharma dive
← prev
page 6 of 6
next →